Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Alkermes plc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
ALKS
Nasdaq
2836
www.alkermes.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Alkermes plc
Should Alkermes’ Stronger Q1 2026 Results and Sleep-Medicine Advances Prompt Action From ALKS Investors?
- Jun 7th, 2026 9:08 pm
Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?
- Jun 5th, 2026 9:30 am
Alkermes (ALKS) Up 21.1% Since Last Earnings Report: Can It Continue?
- Jun 4th, 2026 9:30 am
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
- Jun 4th, 2026 5:00 am
Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
- Jun 3rd, 2026 2:05 pm
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
- May 26th, 2026 5:00 am
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences
- May 21st, 2026 5:00 am
Alkermes' (NASDAQ:ALKS) Soft Earnings Are Actually Better Than They Appear
- May 13th, 2026 12:35 pm
Sector Update: Healthcare Stocks Advance Late Afternoon
- May 12th, 2026 1:58 pm
Sector Update: Healthcare Stocks Gain in Afternoon Trading
- May 12th, 2026 11:54 am
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
- May 12th, 2026 5:00 am
Alkermes' Q1 Revenue Beat Highlights 'Underappreciated' Core Business, RBC Says
- May 6th, 2026 10:37 am
Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises
- May 6th, 2026 10:06 am
Alkermes plc Q1 2026 Earnings Call Summary
- May 5th, 2026 2:46 pm
Alkermes (ALKS) Q1 2026 Earnings Transcript
- May 5th, 2026 2:11 pm
Alkermes Q1 Earnings Call Highlights
- May 5th, 2026 8:14 am
Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
- May 5th, 2026 7:30 am
Alkermes (ALKS) Reports Q1 Loss, Beats Revenue Estimates
- May 5th, 2026 6:25 am
Alkermes plc Reports First Quarter 2026 Financial Results
- May 5th, 2026 5:00 am
Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
- May 1st, 2026 11:24 am
Scroll